| __timestamp | Amicus Therapeutics, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 17268000 |
| Thursday, January 1, 2015 | 47269000 | 19667000 |
| Friday, January 1, 2016 | 71151000 | 27823000 |
| Sunday, January 1, 2017 | 88671000 | 36468000 |
| Monday, January 1, 2018 | 127200000 | 31282000 |
| Tuesday, January 1, 2019 | 169861000 | 39610000 |
| Wednesday, January 1, 2020 | 156407000 | 52820000 |
| Friday, January 1, 2021 | 192710000 | 96803000 |
| Saturday, January 1, 2022 | 213041000 | 177977000 |
| Sunday, January 1, 2023 | 275270000 | 173612000 |
Unleashing insights
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Amicus Therapeutics, Inc. and Cytokinetics, Incorporated have demonstrated distinct spending patterns. From 2014 to 2023, Amicus Therapeutics increased its SG&A expenses by over 1,200%, peaking in 2023. This aggressive investment reflects their commitment to expanding market reach and operational capabilities. In contrast, Cytokinetics, while also increasing its SG&A spending, showed a more conservative growth of approximately 900% over the same period. Notably, in 2022, Cytokinetics' SG&A expenses surged by 84% compared to the previous year, indicating a strategic pivot. These trends highlight the varying strategies employed by biotech firms to navigate the complexities of the industry, balancing between innovation and market expansion.
AbbVie Inc. and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Cytokinetics, Incorporated
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.